Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
HRN01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
HRN01: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Allogeneic dental pulp mesenchymal stem cell therapy (Beijing SH Bio-Tech Corporation/Utooth Biological Technology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Allogeneic dental pulp mesenchymal stem cell therapy (Beijing SH Bio-Tech Corporation/Utooth Biological Technology): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evide
9 min read
DX126-262 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
DX126-262: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
RK-4 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
RK-4: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
VERVE-102 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
VERVE-102: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Recombinant human anti-OX40 monoclonal antibody(Eucure Pharmaceutical Technology (Beijing) Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Recombinant human anti-OX40 monoclonal antibody(Eucure Pharmaceutical Technology (Beijing) Co Ltd): Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review cover
9 min read
Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review c
9 min read
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes(City of Hope National Medical Center) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes(City of Hope National Medical Center): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
TR-4 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
TR-4: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Platelet Rich Plasma-Derived Exosomes(Institute for the Study of Urological Diseases, Greece) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Platelet Rich Plasma-Derived Exosomes(Institute for the Study of Urological Diseases, Greece): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clin
9 min read
Autologous Bone Marrow Mononuclear Cell Transfusion(Vinmec Research Institute of Stem Cell and Gene Technology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Autologous Bone Marrow Mononuclear Cell Transfusion(Vinmec Research Institute of Stem Cell and Gene Technology): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence
9 min read
tRNA-derived fragments-antisense oligonucleotides-exosomes(Affiliated Hospital of Nantong University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
tRNA-derived fragments-antisense oligonucleotides-exosomes(Affiliated Hospital of Nantong University): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review cov